ArticleIn vivo (Athens, Greece)
Impact of Heart Dose on Survival in Palliative Radiotherapy for Bone Metastases: Propensity Score-matched Analysis.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Explainable Deep Learning Model for Predicting Overall Survival in Patients Receiving Palliative Radiotherapy for Bone Metastases.Current oncology (Toronto, Ont.) · 2026Article
- Long-Term Results of a Comparison Between 15 × 2.633 Gy and 20 × 2.0 Gy for Malignant Spinal Cord Compression in Patients with Longer Expected Survival Times.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAlthough the effects of varying heart doses on overall survival (OS) in curative thoracic radiotherapy have been investigated, their impact in palliative settings remains underexplored. This study aimed to examine the impact of heart dose on OS in patients with bone metastases treated with palliative radiotherapy over a three-year follow-up period. MATERIALS AND
methodsThis study included 303 patients who underwent palliative radiotherapy for bone metastases between 2013 and 2022. The primary endpoint was OS, which was evaluated over a fixed three-year follow-up period. To adjust for baseline confounders between patients with and without mean heart dose (MHD) ≥5Gy, we performed 1:1 propensity score matching (PSM) using the following variables: performance status (PS); primary tumor type; number of bone metastases; number of distant metastases (visceral organs, non-regional lymph nodes, and serosal surfaces such as the pleura and peritoneum).
resultsA total of 108 of 303 patients were included after PSM, with 54 patients each in the groups with and without MHD ≥5 Gy. After matching, the baseline characteristics used as matching variables were well balanced, with no significant differences between the groups according to the chi-square test. Kaplan-Meier analysis demonstrated significantly poorer OS in patients with MHD ≥5 Gy than in those without (
conclusionIn propensity score-matched patients receiving palliative, but not curative, radiotherapy, higher MHD was significantly associated with poorer OS over a three-year follow-up period. Furthermore, in the palliative cohort, the MHD level associated with OS may be lower than that in the curative setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.